Meeting Highlights from ObesityWeek 2018

November 11-15, 2018
Music City Center Nashville, TN

Obesity is a multifaceted disease. As the rates continue to rise—in adults as well as children—so do the clinical challenges of addressing, individuals considered overweight or with excessive abdominal fat face a multitude of concomitant comorbidities.

Addressing overweight and patients with obesity is admittedly viewed as one of those necessary evils for all practicing clinicians, and poses a daily challenge for the vast majority of clinicians who have not made weight management their specialty of choice.

Since every clinician sees patients with overweight and obesity, gaining insights into advances in clinical care is of utmost necessity to deliver personalized medicine. As such, EndocrineWeb brings you a selection of presentation highlights from ObesityWeek 2018—the largest international scientific conference focused on the prevention and treatment of obesity hosted by the American Society for Metabolic and Bariatric Surgery and the Obesity Society.

In this way, you can be assured that you are both familiar with and informed about the latest advances in weight management strategies, and ready to respond to your patients' queries and needs.

ObesityWeek 2017 attracted more than 5,500 attendees, who experienced more than 1,200 abstracts, oral presentations, debates, and multi-tracked sessions.

Clinicians convene in Nashville, Tennessee to hear the latest research in weight management.

This comprehensive international continuing medical education conference, spanning five full days, covered topics ranging from prevention and clinical management strategies to emerging innovations and research. The meeting is co-sponsored by the American Society for Metabolic & Bariatric Surgery and the Obesity Society. EndocrineWeb wants to take this opportunity to give a shout out to Caroline Apovian, MD, one of our longest serving and most active members of our Editorial Advisory Board, for her outstanding service as President of the Obesity Society this past year.

An overview of the sessions and presentations encompassed the following:

  • Bariatric surgery: Addressing both the myths and the efficacy of establishing and emerging procedures
  • Food addiction: Setting the record straight
  • Metabolic effects of brown fat, endocrine disruptors, estrogen, ketogenesis, energy expenditure, sleep, genetics
  • Diet, diet, diet: In the news, supporting weight maintenance, unfounded regimens, microbiome, new directions.
  • Much, much more

EndocrineWeb brings you highlights from the following presentations:

Emerging obesity treatments: A closer look at data on two innovative approaches to weight control —Gastric Artery Embolization and Gelisis100 Hydrogel—are reviewed in a session on Innovative and Emerging Pharmacotherapy and Device Forum. The gastric embolization treatment is a non-invasive, outpatient procedure in which minuscule beads are injected into the bloodstream and by lodging in smaller vessels, essentially stop the blood flow to the stomach, remaining in place permanently.1,2  Results of the Get Lean pilot study, a six-month-long program were presented to demonstrate the efficacy. 

The second novel approach, actually a device was discussed with findings presented on the Gelesis100 Loss of Weight (GLOW) study in which findings of the 24-month randomized controlled trials were introduced. This hydrogel pill, given with meals, aims to stimulate satiety by impacting appetite hormones as the food-grade cellulose material passes from the stomach into the small intestine.  

Seeking Sustained Weight Maintenance: The holy grail of weight control would be to identify the means to help people who achieve substantial weight loss to avoid the inevitable weight regain. These investigators proposed prescribing an individualized, low calorie diet plus phentermine following a weight loss period achieved with a very low calorie diet (VLCD). More than 500 men and women were enrolled in this study that was continued for five years.

Combination Pharmacotherapy for TeensCurrently, bariatric surgery is the only effective method to produce substantial weight loss. In an effort to expand the viable, non-surgical options for weight control among a growing number of adolescents with obesity, researchers provided data on the safety and dosing of naltrexone and bupropion to support weight loss. The action center for this dual medication is in the hypothalamus, aiming to prompt appetite suppression.

Unfounded Weight Loss Approaches: Scott Kahan, MD, reported findings of an Obesity Society clinical committee investigation into the evidence supporting the most popular and sought after weight reduction pill, products, and services. The goal was to provide sufficient data to clinicians so patients can be better informed, and frankly warned away from, most of these "snake oil" supplements and overpromised, highly hyped products.

 

 

Last updated on
First Article From This Meeting:
Debunking Weight Loss Products, Pills, Procedures Is Essential to Patient Health
SHOW MAIN MENU
SHOW SUB MENU